imusyn
imusyn GmbH & Co. KG is a Hannover-based German biotechnology company that develops and manufactures recombinant HLA proteins, CE-marked IVD reagents (DaraEx plus) for transfusion medicine, and Dyemer/myDyemer T cell staining reagents for immunology research, IVD manufacturers, and cellular therapy developers.
- Company typePrivate
- Founded2001
- HeadquartersHanover, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What imusyn does
imusyn GmbH & Co. KG is a privately held German biotechnology company founded in 2001 in Hannover that develops and produces recombinant proteins, diagnostic reagents, and T cell staining tools for transfusion medicine, organ transplantation, and immunology research. Its proprietary alloproteomics platform enables high-yield, massively parallel production of recombinant proteins from polymorphic genetic systems — including nearly 100 HLA class I variants, over 70 HLA class II variants, and recombinant blood group antigens (rBGA) — using eukaryotic and prokaryotic expression hosts under a DIN EN ISO 13485 quality management system. Flagship products include the CE-marked IVD reagent DaraEx plus (a patented antigen-masking reagent that overcomes anti-CD38 antibody interference from Daratumumab, Felzartamab, and Isatuximab in pre-transfusion indirect antiglobulin tests), Dyemer and myDyemer T cell staining reagents built on patent-pending disulfide-bridge stabilised HLA class I molecules, and a portfolio of monoclonal antibodies (BBM.1, W6/32 HL, TÜ113, TÜ36, TÜ39).
The company serves three primary customer segments: (1) academic and industrial life sciences researchers and diagnostic assay developers using recombinant HLA proteins and T cell staining reagents for antibody detection, vaccine development, and cancer immunotherapy research; (2) IVD manufacturers and immunohematology laboratories, supplied with CE-marked reagents and recombinant blood group antigens; and (3) vaccine and cellular therapy developers, served by the imuPep peptide/HLA class I binding stability service. Customer relationships include BAG Healthcare (HLA proteins used in HISTO SPOT chip products), with named research use cases also spanning immunology, HLA typing, and T cell immunomonitoring. Product ranges are listed on a downloadable order-form e-commerce shop at imusyn.de, supported by downloadable IFUs in 15 languages for the CE-marked DaraEx plus line.
Revenue is generated through one-time catalog sales of recombinant proteins, RUO reagents, and CE-marked IVD reagents; service fees for imuPep peptide binding analysis, IVD consulting, design & development, and custom recombinant protein production (DIN EN ISO 13485); and quote-based bespoke projects. Distribution is hybrid: a direct online storefront handles RUO catalog sales, while an exclusive distribution partnership with inno-train Diagnostik GmbH (Kronberg, Germany) carries DaraEx plus, DaraEx, and rBGA into European clinical and diagnostic laboratories. Standard catalog pricing (e.g., €944 per 50 µg HLA class II protein, €65 per imuPep peptide/allotype combination) and a €40 handling fee for EU orders under €500 indicate a distributed, transactional revenue model. The company has received an IVDR Confirmation Letter under Regulation (EU) 2024/1860 (May 22, 2025), transitioning CE-marked IVDs under the new regulatory framework with a deadline of December 31, 2027, and holds an EFRE grant supporting the next-generation imuStain multimer staining platform.
imusyn firmographics
Firmographics- Name
- imusyn
- Legal name
- imusyn GmbH & Co. KG
- Website
- https://imusyn.de
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- imusyn GmbH & Co. KG is a Hannover-based German biotechnology company that develops and manufactures recombinant HLA proteins, CE-marked IVD reagents (DaraEx plus) for transfusion medicine, and Dyemer/myDyemer T cell staining reagents for immunology research, IVD manufacturers, and cellular therapy developers.
- Ownership category
- akta.pro rank
imusyn industry classification
Industry- Product category
- Transfusion Medicine & Transplantation Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
- akta.pro secondary industries
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where imusyn is headquartered
LocationHeadquarters
- HQ city
- Hanover
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
imusyn business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Recombinant Protein Sales (HLA, rBGA): Sale of recombinant HLA class I proteins (nearly 100 variants), HLA class II proteins (over 70 variants), recombinant blood group antigens (rBGA), and T cell staining reagents (Dyemer/myDyemer) as research use only (RUO) products. Products are sold via the company's online shop and through distribution partners. Customers include life sciences researchers, diagnostic assay developers, and IVD manufacturers.
- DaraEx / DaraEx plus IVD Diagnostic Reagent Sales: DaraEx plus is sold as a CE-marked IVD medical device through distribution partner inno-train Diagnostik GmbH. DaraEx (RUO) is also available through the same distributor. Revenue is generated through product sales to immunohematology laboratories and blood transfusion services.
- imuPep Class I Peptide Binding Analysis Service: Fee-for-service high-throughput peptide/HLA class I binding stability analysis. Customers can order per peptide/HLA allotype combination. Peptide synthesis can be added as an optional service. The service is quoted and ordered via downloadable order form.
- IVD Consulting Services: Regulatory consulting for in-vitro diagnostic development, including technical documentation preparation and compliance support under European IVDR. Supports clients from concept through CE marking.
- Custom Recombinant Protein Production: Full-service custom recombinant protein production under DIN EN ISO 13485. Clients can enter the process at any stage: gene cloning, cell line cultivation, or purification of crude material. Offered as a bespoke service with project-based pricing.
- Design & Development Consulting: Protein design and antigen development consulting, including optimisation of protein stability, epitope expression, and production yields. Provided either as an in-house service or as on-site consulting at the client's company.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Recombinant HLA Class II Proteins (e.g., HLA-DQA1*01:01-DQB1*06:02) — 50 µg unit at 0.5 mg/ml |
| Unit Pricing | Pay-as-you-go | EU Shipping and Handling Fee |
| Unit Pricing | Pay-as-you-go | imuPep Class I Peptide Binding Analysis — per peptide/allotype combination |
| Unit Pricing | Pay-as-you-go | Peptide Synthesis Service (for imuPep) |
| Other | Pay-as-you-go | Custom/HLA alleles and T cell staining reagents not in catalog |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
imusyn product offering
Product offeringCore offering
imusyn develops and manufactures recombinant proteins and IVD reagents for transfusion medicine and organ transplantation. Its core offerings include nearly 100 recombinant HLA class I proteins, over 70 HLA class II proteins, the DaraEx/DaraEx plus line of IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing, and Dyemer/myDyemer T cell staining reagents for antigen-specific CD8+ T cell detection. The company also delivers fee-for-service peptide binding analysis, IVD consulting, custom recombinant protein production, and protein design and development services under DIN EN ISO 13485 quality management.
Product overview
imusyn is a biotechnology company specializing in recombinant proteins for transfusion medicine and organ transplantation diagnostics. The product portfolio centers on three main areas: (1) Recombinant HLA Class I and Class II proteins (nearly 100 and over 70 molecules respectively) for antibody detection in transplantation; (2) DaraEx and DaraEx plus — patented IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing; and (3) Dyemer and myDyemer — novel T cell staining reagents for antigen-specific CD8+ T cell detection. The company also offers monoclonal antibodies (W6/32 HL, BBM.1, TÜ113, TÜ36, TÜ39) for research use. Services include imuPep Class I Peptide Binding Analysis (high-throughput peptide/HLA stability testing), IVD Consulting, Design & Development, and Custom Production — all delivered under DIN EN ISO 13485 quality management.
Differentiator
Problem solved
Functional benefit
Brands
- DaraEx: Patented reagent to overcome anti-CD38 antibody interference in immunohematological pre-transfusion testing, including DaraEx plus (CE marked IVD) and DaraEx (RUO).
- Dyemer & myDyemer
- imuStain
- imuPep
- rBGA
Products and services
- Recombinant HLA Class I Proteins Recombinant, truncated, soluble HLA class I proteins produced in mammalian cell culture for antibody detection in transplantation and transfusion medicine. imusyn offers nearly 100 recombinant HLA class I molecules including HLA-A, HLA-B, and HLA-C alleles, sold for research use only (RUO).
- Recombinant HLA Class II Proteins Recombinant HLA class II proteins (DR, DP, DQ antigens) produced as zipper-stabilized heterodimers in mammalian cell culture for use in antibody detection and immunoassays. Over 70 recombinant HLA class II molecules are available for research use only (RUO).
- DaraEx plus CE-marked IVD reagent that overcomes anti-CD38 antibody interference (Daratumumab, Felzartamab, Isatuximab) in indirect antiglobulin tests (IAT) using patented antigen-masking (AMIAT) technology. Sold as a one-step treatment for red blood cells in pre-transfusion compatibility testing.
- DaraEx Research use only (RUO) reagent for overcoming anti-CD38 antibody interference in pre-transfusion testing using the same patented antigen-masking technology as DaraEx plus.
- Dyemer Novel T cell staining reagent for detection and enumeration of antigen-specific CD8+ T cells. Comprises recombinant MHC class I molecules expressed in mammalian cell culture with authentic glycosylation, coupled to fluorophore-labeled streptavidin (PE or APC conjugate). Features reversible staining capability via biotin incubation.
- myDyemer Peptide-receptive, pre-multimerized T cell staining reagent that remains stable in a peptide-deficient state, allowing users to load their peptide of interest by single-step peptide addition without refolding assays. Based on imuStain disulfide-bridge-stabilised HLA class I technology.
- Monoclonal Antibodies Research use monoclonal antibodies including BBM.1 (Beta-2-microglobulin), PR1F11F11 (V5-tag), W6/32 HL (MHC class I), TÜ113 (HLA class I), TÜ36 (HLA class II), and TÜ39 (HLA class II), available unconjugated or HRP-conjugated.
- Recombinant Blood Group Antigens (rBGA) Recombinant blood group antigens available for research use only (RUO), distributed through inno-train Diagnostik GmbH for antibody detection applications in immunohematology.
- imuPep Class I Peptide Binding Analysis High-throughput fee-for-service using differential scanning fluorimetry (DSF) and native PAGE to determine the stability of peptide/HLA class I complexes. Supports over 60 HLA class I allotypes for rapid assessment of immunogenic peptide stability in vaccine development, cancer research, and T cell epitope identification.
- IVD Consulting Regulatory and technical consulting for the development and production of in-vitro diagnostic tests, including technical documentation preparation and CE marking support under the European IVDR.
- Design & Development Expertise in protein design and antigen development to optimize protein stability, epitope expression, and production yields. Delivered either as an in-house service or as on-site consulting at the client's site.
- Custom Production Full-service custom recombinant protein production in accordance with DIN EN ISO 13485, covering all stages from gene cloning and cell line cultivation through purification of crude material. Clients can enter the process at any stage.
Quantifiable outcome
- DaraEx and DaraEx plus successfully mitigate interference from anti-CD38 antibodies (Daratumumab, Felzartamab, Isatuximab) in indirect antiglobulin tests without affecting detection of other clinically relevant antibodies (e.g., anti-Kell)
- +1 more outcomes
Companies that use imusyn
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
imusyn technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
imusyn partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- inno-train Diagnostik GmbHcoreinno-train Diagnostik GmbH is the exclusive distribution partner for imusyn's DaraEx plus (CE-marked IVD), DaraEx (RUO), and rBGA products. The partnership extends imusyn's commercial reach into clinical laboratory and diagnostic markets across Europe. Located at Niederhöchstädter Str. 62, 61476 Kronberg, Germany. DaraEx plus is available from inno-train's retail portal at www.inno-train.de.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
imusyn competitors and assessment
Company assessmentDirect peers
- GenDx: GenDx develops and commercializes HLA typing and antibody detection reagents for transplantation diagnostics. Its SBT and NGS-based HLA products overlap with imusyn's recombinant HLA protein portfolio serving transplant and immunohematology laboratories.
- ProImmune: ProImmune supplies MHC tetramers, peptide binding assays (REVEAL®), and recombinant HLA proteins for immunology research and immunotherapy development. It is the closest direct competitor to imusyn's Dyemer/myDyemer multimer staining reagents and imuPep peptide binding analysis service.
- Immucor: Immucor is a specialist in transfusion and transplantation diagnostics, offering blood bank reagents and HLA antibody detection assays. It competes with imusyn's DaraEx plus and recombinant blood group antigens in the immunohematology laboratory market.
Broad incumbents
- One Lambda (Thermo Fisher Scientific): One Lambda, part of Thermo Fisher Scientific, is a leading provider of HLA typing, antibody detection, and transplant diagnostics products. It is a broader incumbent with overlapping HLA antibody detection reagents that compete with imusyn's recombinant HLA portfolio.
- Miltenyi Biotec: Miltenyi Biotec supplies reagents and instruments for cell analysis, including MHC multimers and T cell research tools. It overlaps with imusyn's Dyemer/myDyemer reagents and serves similar immunology and cell therapy research customers.
- Bio-Rad Laboratories: Bio-Rad offers a broad portfolio of blood bank and HLA typing products through its diagnostics division. Its size and commercial reach make it a broad incumbent competitor to imusyn's immunohematology and transplantation diagnostics products.
Emerging players
- Creative Biolabs: Creative Biolabs offers custom recombinant protein production and MHC/peptide reagent services for research use. It is an emerging player overlapping with imusyn's custom production and recombinant HLA protein catalog offerings.
- CellGenix: CellGenix manufactures recombinant proteins and cell therapy manufacturing reagents under GMP. It shares imusyn's focus on high-quality recombinant protein production and serves adjacent cell and gene therapy developers.
Others
- inno-train Diagnostik GmbH: inno-train Diagnostik is imusyn's exclusive distribution partner for DaraEx plus, DaraEx, and rBGA products. It is an ecosystem participant and adjacent supplier of flow cytometry and HLA diagnostic reagents in Europe.
- BAG Healthcare: BAG Healthcare is an imusyn customer that integrates imusyn's recombinant HLA proteins into its HISTO SPOT diagnostic chip products. It is thematically adjacent as a downstream IVD manufacturer in transplantation diagnostics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
imusyn social profiles
Digital presenceimusyn compliance and trust
Trust signalCompliance3 records
imusyn financial estimates
Financial estimateRevenue estimate
Valuation estimate
imusyn leadership team
Management profileNumber of profiles
Profiles2 records
imusyn funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
imusyn M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about imusyn
What does imusyn do?
imusyn develops and manufactures recombinant proteins and IVD reagents for transfusion medicine and organ transplantation. Its core offerings include nearly 100 recombinant HLA class I proteins, over 70 HLA class II proteins, the DaraEx/DaraEx plus line of IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing, and Dyemer/myDyemer T cell staining reagents for antigen-specific CD8+ T cell detection. The company also delivers fee-for-service peptide binding analysis, IVD consulting, custom recombinant protein production, and protein design and development services under DIN EN ISO 13485 quality management.
Is imusyn a public or private company?
imusyn is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was imusyn founded?
imusyn was founded in 2001. It employs 1 to 10 people.
Where is imusyn based?
imusyn is headquartered in Hanover, Germany, in the Europe region.
How does imusyn make money?
Six revenue lines are on record. Recombinant Protein Sales (HLA, rBGA) is the primary driver. The others are daraEx / DaraEx plus IVD Diagnostic Reagent Sales, imuPep Class I Peptide Binding Analysis Service, IVD Consulting Services, custom Recombinant Protein Production and design & Development Consulting.
Who are imusyn's main competitors?
Direct peers on record are GenDx, ProImmune and Immucor. Broad incumbents are One Lambda (Thermo Fisher Scientific), Miltenyi Biotec and Bio-Rad Laboratories. Emerging players are Creative Biolabs and CellGenix. Others are inno-train Diagnostik GmbH and BAG Healthcare.
Does imusyn have an API?
No public API is recorded for imusyn.
What industry is imusyn in?
imusyn's product category is Transfusion Medicine & Transplantation Diagnostics. Its primary akta.pro industry code is HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls), with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.